Tinidazole in the treatment of bacterial vaginosis

Nicola R Armstrong¹
Janet D Wilson²

¹Department of Infectious Diseases and Sexual Health, Trinity Centre, Bradford, UK; ²The Centre for Sexual Health, The General Infirmary at Leeds, Leeds, UK

Abstract: Bacterial vaginosis (BV) is the commonest cause of vaginal discharge in women of childbearing age. Oral metronidazole has long been established as an effective therapy in the treatment of BV. However, adverse effects due to metronidazole are frequent and this may lead to problems with adherence to a 7-day course of treatment and subsequently result in treatment failure. Oral tinidazole has been used to treat bacterial vaginosis for over 25 years but in a number of different dosage regimens. Placebo controlled trials have consistently shown increases in cure rate with tinidazole. Longer courses of treatment (e.g., 1 g daily for 5 days) appear to be more effective than a 2 g oral single dose. Comparative studies suggest that oral tinidazole is equivalent to oral metronidazole, intravaginal clindamycin cream, and intravaginal metronidazole tablets, in efficacy in treating BV. However, tinidazole has a more favorable side effect profile than oral metronidazole notably with better gastrointestinal tolerability and less metallic taste. Bacterial vaginosis is associated with high rates of recurrence and appropriate management of such recurrences can prove difficult. Recurrent BV has been linked with persistence of Gardnerella vaginalis after treatment; however, the clinical implications of the possible greater activity of tinidazole against G. vaginalis are not yet clear. Repeated courses of oral metronidazole may be poorly tolerated and an alternative but equally effective treatment that is better tolerated may be preferable. In comparison to oral metronidazole, cost is clearly an issue as oral metronidazole is considerably cheaper and available in generic form. However, where avoidance of oral metronidazole is necessary because of side effects, oral tinidazole is a cost-effective alternative.

Keywords: bacterial vaginosis, tinidazole, metronidazole, Gardnerella vaginalis

Introduction

Bacterial vaginosis (BV) is the commonest cause of vaginal discharge in women of childbearing age. It is characterized by a thin homogenous white discharge, a vaginal pH of greater than 4.5, a positive amine test and the presence of clue cells microscopically. There is a change from the normal lactobacilli (LB) dominant vaginal flora, with hydrogen peroxide production, to flora with greatly reduced numbers of LB and an increase in the concentration and prevalence of organisms including Gardnerella vaginalis, Mycoplasma hominis and anaerobic bacteria such as peptostreptococci, Prevotella spp., and Mobiluncus spp.¹ Recently Atopobium vaginae, and some non-culturable species identified by molecular analysis (named BV associated bacteria [BVAB]), have also been found in association with BV.²⁻³

The diagnosis of bacterial vaginosis can be made using the Amsel’s clinical criteria.⁴ Three of the following should be present: thin homogenous white discharge, vaginal
pH greater than 4.5, amine odor after adding 10% potassium hydroxide to vaginal fluid, and clue cells on microscopy (at least 1 in 5 vaginal epithelial cells). Alternatively, a vaginal smear can be Gram-stained and scored microscopically as according to Nugent. The scoring is between 0 and 10 based on the relative quantities of various bacteria. Scores of 7 to 10 are consistent with BV, 4 to 6 indicate intermediate flora and 0 to 3 are normal flora.

The pathogenesis of BV is not yet clearly understood. BV has been associated with a number of complications including risk of late miscarriage and preterm birth, postoperative infections including postabortion-PID, posthysterectomy cuff cellulitis and postcesarean endometritis, and possibly pelvic inflammatory disease (PID). It has also been associated with an increased risk of acquiring HIV-1 infection.

Oral metronidazole has long been established as an effective therapy in the treatment of BV. Intravaginal preparations of metronidazole and clindamycin have also been widely used. In 1999 Joesoef et al updated their previous publication which had reviewed treatment options for BV. The additional published studies on the treatment of bacterial vaginosis from 1993 through to 1996 were reviewed. Their first-line recommended treatments in nonpregnant women were oral metronidazole 500 mg twice daily for 7 days, or clindamycin vaginal cream 2% once daily for 7 days, or metronidazole vaginal gel 0.75% twice daily for 5 days. There were no statistically significant differences in cumulative cure rates between these treatments. Their previous paper had identified that the 7-day regimen of oral metronidazole was more efficacious than the single dose regimen of 2 g of metronidazole (the cumulative cure rates 3 to 4 weeks after completion of treatment were 82% vs 62%).

However, adverse effects due to metronidazole are frequent, and this may lead to problems with adherence to a 7-day course of treatment and subsequently result in treatment failure. Consequently, other drugs of the nitroimidazole class have been explored as alternatives to metronidazole for the treatment of BV.

Tinidazole, 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitroimidazole, was first introduced into clinical medicine in 1967 for the treatment of Trichomonas vaginalis infections. It has subsequently been used for the treatment of other protozoal infections including giardiasis and amoebiasis, in the eradication of Helicobacter pylori infection, and in anaerobic infections such as intraperitoneal infections, postoperative wound infections, skin and soft tissue infections and gynecological infections including BV. Here we review both the pharmacological profile of tinidazole and the evidence for its efficacy in the treatment of BV.

**Mechanism of action, pharmacokinetics and metabolism**

Tinidazole is a prodrug that is converted to cytotoxic forms in vivo. It has a low molecular weight and penetrates the cell membrane of both aerobic and anaerobic microorganisms. After diffusing into the cells of susceptible organisms, tinidazole is reduced at its nitro group to short lived toxic radicals by a ferredoxin-mediated transport system. It is thought that these toxic intermediates bind to DNA resulting in DNA damage which ultimately leads to cell death. Most aerobic bacteria are unable to generate the toxic radicals and are thus not susceptible to tinidazole.

A pharmacokinetic comparison of oral tinidazole 500 mg and oral metronidazole 500 mg showed tinidazole to have a significantly higher $C_{\text{max}}$, area under the curve, and longer half-life. Both drugs achieve good tissue levels in the female reproductive tract at 70% to 100% of those of the simultaneous serum levels. However, the steady-state serum concentration of tinidazole following oral administration was higher than that of metronidazole. The half-life of tinidazole is 12.7 hours and the antimicrobial plasma concentrations maintained in the tissues are sufficient to permit once daily dosing. The pharmacokinetic properties are similar after oral doses of 2000 mg and intravenous doses of 800 mg and 1600 mg. It is minimally bound to plasma protein (12%) and is widely distributed in all body tissues.

Elimination is primarily by hepatic metabolism (approximately 63%). Due to lack of data, use of tinidazole in patients with severe hepatic impairment is not recommended. No adjustment of the tinidazole dosage appears to be necessary based on renal function.

**In vitro activity**

Tinidazole is active against anaerobic protozoa including *T. vaginalis, E histolytica* and *G lamblia*. It also has in vitro activity against most anaerobic bacteria including *Bacteroides, Fusobacterium* and *Clostridium* spp. Two comparative in vitro studies showed minor enhanced in vitro activity against *G. vaginalis* with tinidazole compared to metronidazole. More recently, antimicrobial susceptibility testing to metronidazole and tinidazole was performed on 470 vaginal isolates from women with bacterial vaginosis. The overall spectrum of activity against the BV-associated bacteria was very similar. *Lactobacillus* isolates were the least susceptible to tinidazole and metronidazole with 96%
and 100% of Lactobacillus isolates showing resistance. This was expected as facultative organisms are generally not inhibited by nitroimidazoles because the reduction of the nitro group is dependent upon the absence of oxygen. Of the G. vaginalis isolates 54% and 68% were resistant to tinidazole and metronidazole respectively. 15% of the G. vaginalis isolates were resistant to metronidazole but susceptible to tinidazole, whereas only one isolate was susceptible to metronidazole and resistant to tinidazole (P = 0.001). Tinidazole therefore shows activity against anaerobes similar to that of metronidazole with slightly greater activity against G. vaginalis. Mobiluncus spp. are resistant to both metronidazole and tinidazole with similar MICs. Atopobium vaginae also appears to be highly resistant to metronidazole, but susceptibility testing to tinidazole was not performed.2

There are no efficacy data against the newly identified non-cultur able bacteria associated with BV.

Studies of tinidazole and BV

Oral tinidazole has been used to treat bacterial vaginosis for over 25 years but in a number of different dosage regimens. There have been a number of published clinical studies but unfortunately there are several problems in trying to compare and evaluate these trials. Many were carried out prior to the universally recognized diagnostic clinical criteria of Amsel4 and the Nugent Gram stain score5 and before the use of the term ‘bacterial vaginosis’ was introduced when the condition was known as non specific vaginitis. Furthermore there are differences in the dosing and duration of tinidazole used, ranging from 1 to 2 g daily for 1 to 5 days, and also in the comparator drug.

Comparison of treatment trials for BV has been recognized as being complex. In 1992 Larsson reviewed treatments of bacterial vaginosis.23 He cited the following differences between treatment studies: the criteria used for the diagnosis of BV vary; different exclusion criteria are used; the definition of cure varies; the timing of treatment evaluation varies; and some studies are double-blind placebo controlled trials whereas others are open trials.23 In order to try to overcome these differences, in 1998, the FDA issued a draft guidance document entitled “Bacterial Vaginosis — Developing Antimicrobial Drugs for Treatment”.24 This called for investigators to define BV in study participants as the presence of all four of Amsel’s criteria plus a Nugent score of 7 to 10, and to perform the examination for evaluation of therapeutic response at 21 to 30 days after the first few days of treatment. It recommended that cure should be defined as absence of all four Amsel’s criteria plus a Nugent score of 0 to 3. While these recommendations may ensure uniformity amongst trial evaluations, such a strict definition of cure may not necessarily identify differences between treatment efficacies. An example of variation in treatment results using the different methods of evaluation was shown in a comparison of two intravaginal metronidazole regimens for the treatment of BV.25 The authors observed a significant difference between the two regimens at follow up when BV was defined by the presence of at least three of four Amsel’s criteria, or a Nugent score of 7 to 10, or both. However, no significant difference in rates of cure was found using the 1998 FDA draft guidance definition of cure.25 Only the most recently published study comparing two different doses of tinidazole to treat BV has used the FDA definition of cure.26

Although comparison between different treatment studies is difficult, placebo controlled trials have consistently shown increases in cure rate with tinidazole (see Table 1).26–30 The cure rates with tinidazole ranged from 46% to 71% for tinidazole 2 g oral single dose, 74% for 2 g daily for 2 days and 91% for the 1 g daily for 5 days dose.27–30 Comparative studies suggest that oral tinidazole is equivalent to oral metronidazole,20,31–35 intravaginal clindamycin cream,33,35 and intravaginal metronidazole tablets,16 in efficacy in treating BV. There are no data comparing oral tinidazole with intravaginal metronidazole gel.

In 2007 Nailor and Sobel reviewed 21 clinical efficacy studies evaluating tinidazole for bacterial vaginosis.37 They concluded that compared with placebo, tinidazole in all studied regimens consistently demonstrated at least short term efficacy in eradicating signs and symptoms of BV. Tinidazole 2 g/day (single daily dose) for 2 days appeared more effective than a single tinidazole 2 g dose (1 day dose). A lower daily dose (500 mg twice daily or 1 g once daily) taken for a longer period, for example 5 days, was also highly effective.37 Following that review, Livengood et al36 published the results of a randomized controlled trial assessing the effectiveness of tinidazole orally 1 g once daily for 5 days and 2 g once daily for 2 days, compared with placebo, in the treatment of bacterial vaginosis. Follow up was at 21 to 30 days after treatment, using the strict FDA recommended criteria to define cure. Cure rates were 36.8% for the 1 g daily for 5 days regimen, 27.4% for the 2 g daily for 2 days regimen and 5.1% for the placebo group. They concluded that both regimens gave significantly higher cure rates than placebo and are an effective treatment for BV. The 1 g once daily for 5 days regimen showed trends toward better efficacy and
Whether or not tinidazole has better efficacy than metronidazole is currently impossible to say. When the same drug dose and duration have been compared (ie, 2 g single day dose) tinidazole has had higher cure rates than metronidazole.\textsuperscript{20,35} However, it is now recognized that single dose oral therapy is not as effective as a longer course and metronidazole 2 g single dose is no longer recommended as first-line therapy for BV.\textsuperscript{11,38} There has been no published head-to-head comparison of the more effective oral metronidazole regimen (500 mg twice daily for 7 days) with the more effective tinidazole regimen (1 g daily for 5 days). Such a study is needed to clarify if there are any differences in cure rates of BV between the two treatments.

Recurrences of bacterial vaginosis are frequent and appropriate management can prove difficult.\textsuperscript{1} Persistence of \emph{G. vaginalis},\textsuperscript{39} \emph{Atopodium vaginae},\textsuperscript{39} \emph{Mobiluncus curtisii},\textsuperscript{40} and the BVAB\textsuperscript{41} after treatment has been linked with recurrences of BV. Both metronidazole and tinidazole appear to be ineffective against \emph{M. curtisii}, however the clinical implications of the possible greater activity of tinidazole against \emph{G. vaginalis} are not yet clear.\textsuperscript{21} Repeated courses of oral metronidazole may be poorly tolerated and an alternative equally effective treatment that is better tolerated may be preferable.

### Current recommended use of tinidazole

The 2006 UK National Guidelines for the management of bacterial vaginosis currently recommend oral metronidazole as first-line treatment with tinidazole 2 g single oral dose as an alternative.\textsuperscript{42} The 2004 Australasian College of Sexual Health Physicians Clinical Guidelines for the management of sexually transmissible infections among priority populations list tinidazole 2 g single oral dose for the treatment of bacterial vaginosis but caution that the cure rate may be lower than a longer course of treatment.\textsuperscript{43}

### Table 1

<table>
<thead>
<tr>
<th>Reference</th>
<th>No. in study</th>
<th>Tinidazole cure rate (%)</th>
<th>Comparators, doses and cure rates (%)</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>\textsuperscript{2} g (and 1 g bid) studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pauwonen 1983\textsuperscript{27}</td>
<td>33</td>
<td>71</td>
<td>38</td>
<td>27</td>
</tr>
<tr>
<td>van der Meiden 1983\textsuperscript{29}</td>
<td>26</td>
<td>46</td>
<td>8</td>
<td>29</td>
</tr>
<tr>
<td>Ekgren 1988\textsuperscript{20}</td>
<td>247</td>
<td>51</td>
<td>4</td>
<td>74 (tinidazole 2 g × 2 days)</td>
</tr>
<tr>
<td>Mohanty 1987\textsuperscript{30}</td>
<td>280</td>
<td>92</td>
<td>79 (2 g)</td>
<td>88 (nimorazole)</td>
</tr>
<tr>
<td>Milani 2003\textsuperscript{31}</td>
<td>89</td>
<td>88</td>
<td>73 (2 g)</td>
<td>35</td>
</tr>
<tr>
<td>Sanz-Sanz 1985\textsuperscript{31} (1 g bid)</td>
<td>80</td>
<td>65</td>
<td>74 (500 mg bid × 7 days)</td>
<td>31</td>
</tr>
<tr>
<td>Buranawarodomkul 1990\textsuperscript{13}</td>
<td>100</td>
<td>86</td>
<td>92 (500 mg bid × 7 days)</td>
<td>32</td>
</tr>
<tr>
<td>Sanz-Sanz 1996\textsuperscript{33}</td>
<td>230</td>
<td>75</td>
<td>80 (500 mg bid × 7 days)</td>
<td>33</td>
</tr>
<tr>
<td>Milani 2003\textsuperscript{34}</td>
<td>64</td>
<td>94</td>
<td>82 (400 mg bid × 5 days intravaginal tablet)</td>
<td>36</td>
</tr>
<tr>
<td>Schindler 1991\textsuperscript{36}</td>
<td>75</td>
<td>84</td>
<td>63 (ornidazole 1 g bid × 2 days)</td>
<td>31</td>
</tr>
<tr>
<td>2 g × 2-day or 2 g × 3-day studies (or 1 g bid × 2 or 3 days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sanz-Sanz 1985\textsuperscript{31}</td>
<td>60</td>
<td>50 (1 g bid × 2 days)</td>
<td>4</td>
<td>51 (tinidazole 2 g)</td>
</tr>
<tr>
<td>Ekgren 1988\textsuperscript{20}</td>
<td>247</td>
<td>74 (2 g × 2 days)</td>
<td>5.1</td>
<td>26</td>
</tr>
<tr>
<td>Livengood 2007\textsuperscript{26}</td>
<td>235</td>
<td>27.4 (2 g × 2 days)</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>1 g × 5-day studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Piot 1983\textsuperscript{38} (500 mg bid × 5 days)</td>
<td>57</td>
<td>91</td>
<td>40</td>
<td>44 (intravaginal, sulfa bid × 7 days)</td>
</tr>
<tr>
<td>Livengood 2007\textsuperscript{26}</td>
<td>235</td>
<td>36.8</td>
<td>5.1</td>
<td>26</td>
</tr>
</tbody>
</table>
The 2001 European,44 the 2003 WHO,45 the 2006 US,36 and the 2008 Canadian46 guidelines do not include tinidazole as a preferred or alternative option in the treatment of bacterial vaginosis. Of note is that the US Food and Drug Administration (FDA) only approved tinidazole for the treatment of bacterial vaginosis in May 2007 based on the results of the Livengood study.26 This approval was after the publication of the current 2006 sexually transmitted diseases treatment guidelines.

**Safety and tolerability**

There is substantial information regarding the tolerability of tinidazole and its safety profile. It seems to be free from clinical toxicity following standard oral and intravenous doses. Apte and Packard evaluated the safety of tinidazole in 1517 adult and pediatric patients.47 Of these, 143 patients (9.4%) experienced one or more adverse event. The most frequently encountered adverse events were nausea (3.6%), abdominal discomfort (2.4%), vomiting (1.7%), anorexia (1.3%), constipation (1.2%), headache (0.9%), and a dry mouth (0.6%).47 An analysis of the results of 5 randomized controlled trials comparing tinidazole with metronidazole for the treatment of 99 patients with confirmed amoeba liver abscess reported gastrointestinal adverse events in 6% of patients receiving tinidazole and 41% of patients receiving metronidazole.48 Patients who received metronidazole experienced significantly more nausea (36.7% with metronidazole versus 6.0% with tinidazole; \( P \leq 0.01 \)), anorexia (28.6% versus 4.0%; \( P \leq 0.01 \)), vomiting (24.4% versus 0%) and metallic taste (18.4% versus 0%).48

Adverse events associated with tinidazole are usually mild and self-limiting. Hypersensitivity reactions have however been reported, presenting as angioedema, periorbital and laryngeal edema, bronchospasm, dyspnea, fixed drug eruptions and generalized urticaria. There have been reports of peripheral neuropathy and convulsions associated with metronidazole use, so it is recommended that tinidazole should be used with caution in patients with central nervous system syndromes and abnormalities.15

Tinidazole crosses the placental barrier. Since the effects of compounds of this class on fetal development are unknown, the manufacturers recommend avoidance during the first trimester. There is no evidence that it is harmful during the latter stages of pregnancy, but its use during the second and third trimesters requires the potential benefits be weighed against possible hazards to mother or fetus (Summary of Product Characteristics [SPC] Fasigyn®; Pfizer Ltd, Ramsgate Road, Sandwich, Kent, UK).

**Interactions**

Like metronidazole, concurrent use of tinidazole with alcohol may produce a disulfiram-like reaction and should be avoided. Drugs of similar chemical structure have been shown to potentiate the effects of oral anticoagulants and it is advised that prothombin time be monitored closely (SPC). Co-administration of lithium and metronidazole may increase the risk of lithium toxicity. It is not known if this interaction occurs with other nitroimidazoles but close monitoring of lithium levels would be advised when given with tinidazole.

**Cost**

Oral metronidazole is the least expensive of all established treatments for bacterial vaginosis. The British National Formulary quotes the current UK price49 as £1.29 for a 21-tablet pack of 400 mg tablets. Metronidazole 0.75% intravaginal gel 40 g pack costs £4.31 compared to £10.86 for clindamycin 2% intravaginal cream 40 g pack. Oral tinidazole has a price of £13.80 for a 20-tablet pack of 500 mg tablets meaning a 2 g single dose costs £2.76 and 1 g daily for 5 days regimen costs £6.90 (see Table 2). Therefore, if an alternative to oral metronidazole is required, oral tinidazole compares favorably in terms of cost with both metronidazole and clindamycin intravaginal preparations.

**Table 2** Approximate costs of treatment regimens for bacterial vaginosis from British National Formulary March 200949

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose and duration</th>
<th>Cost (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral metronidazole</td>
<td>400 mg/500 mg twice daily for 7 days</td>
<td>0.86</td>
</tr>
<tr>
<td>Oral metronidazole</td>
<td>2 g single dose</td>
<td>0.31</td>
</tr>
<tr>
<td>Metronidazole 0.75% intravaginal gel, 40 g pack</td>
<td>5 g applicator per night for 5 nights</td>
<td>4.31</td>
</tr>
<tr>
<td>Clindamycin 2% intravaginal cream, 40 g pack</td>
<td>5 g applicator per night for 7 nights</td>
<td>10.86</td>
</tr>
<tr>
<td>Oral tinidazole</td>
<td>1 g daily for 5 days</td>
<td>6.90</td>
</tr>
<tr>
<td>Oral tinidazole</td>
<td>2 g single dose</td>
<td>2.76</td>
</tr>
</tbody>
</table>
Conclusion

Tinidazole shows proven efficacy in the treatment of BV. The cure rates are comparable to those of metronidazole, but clinical superiority has not been demonstrated. However, tinidazole has a more favorable side effect profile, notably with better gastrointestinal tolerability and less metallic taste, both of which are often implicated in poor adherence to metronidazole therapy. Comparative studies suggest that oral tinidazole is equivalent to intravaginal clindamycin cream and intravaginal metronidazole tablets in efficacy in the treatment of BV. The optimal dose and duration of tinidazole has not been established but it appears that longer courses are better than single day therapy.

Bacterial vaginosis is associated with high rates of recurrence and appropriate management of such recurrences can prove difficult. Recurrent BV has been linked with persistence of G. vaginalis after treatment; however the clinical implications of the possible greater activity of tinidazole against G. vaginalis are not yet clear. Repeated courses of oral metronidazole may be poorly tolerated and an alternative but equally effective treatment that is better tolerated may be preferable.

In comparison to oral metronidazole, cost is clearly an issue as metronidazole is considerably cheaper and available in generic form. However where avoidance of oral metronidazole is necessary because of side effects, oral tinidazole is a cost-effective alternative.

Disclosures

The authors declare no conflicts of interest.

References


